<DOC>
	<DOCNO>NCT00144859</DOCNO>
	<brief_summary>This 28-day , placebo control clinical study assess safety , tolerability anti-inflammatory effect pharmacokinetics SB681323 patient COPD ( Chronic Obstructive Pulmonary Disease ) .</brief_summary>
	<brief_title>Safety And Anti-Inflammatory Effect Of SB681323 In Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>Inclusion criterion : Nonchildbearing potential . Clinical diagnosis COPD . Cigarette smoke history great equal 10 pack year . Postbronchodilator FEV1 FVC ratio ( FEV1 : FVC ) &lt; 0.7 Postbronchodilator FEV1 50 % 80 % predict normal . Receiving inhaled corticosteroid minimum 6 week prior Screening . Serum CRP concentration great 3mg/L . Exclusion criterion : Current diagnosis asthma . Active tuberculosis , sarcoidosis bronchiectasis . History type malignancy , rheumatoid arthritis condition associate chronic inflammation . Clinically significant renal hepatic disease . History increase liver function test , patient receive hormone replacement therapy , statins systemic topical corticosteroid .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>P38 map kinase</keyword>
	<keyword>CRP</keyword>
	<keyword>COPD</keyword>
	<keyword>safety</keyword>
</DOC>